On August 25, Moderna, Inc. rose 4.3% in regular trading, trading at $148.99/share, with turnover of $397 million. The stock remains in a volatile price reassessment phase following its historic 177% surge triggered by the mRNA cancer vaccine Phase III trial success.

On the news front, Barclays raised its price target on Moderna from $48 to $125, while the stock continues to digest the landmark announcement that its personalized mRNA cancer vaccine intismeran autogene, co-developed with Merck, achieved the primary endpoint in the Phase III INTerpath-001 trial for high-risk melanoma. This represents the first mRNA cancer therapy to deliver positive results in a randomized controlled Phase III trial. Multiple Wall Street firms have significantly raised targets, with BofA upgrading to Neutral with a $170 target, Jefferies raising to $150, and Piper Sandler setting $167. The options market reflects extreme volatility with IV percentile at 99.6%, indicating intense bull-bear debate as the stock stabilizes after its initial 23.5% pullback and 16% rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)